Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03745144 (ClinicalTrials.gov)	January 17, 2019	14/11/2018	Effects of Cladribine Tablets on the PK of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck KGaA, Darmstadt, Germany	NULL	Active, not recruiting	18 Years	45 Years	Female	24	Phase 1	Germany;Poland
2	NCT04086225 (ClinicalTrials.gov)	January 17, 2019	9/9/2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NULL	Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
3	EUCTR2014-005129-10-FI (EUCTR)	27/01/2015	12/12/2014	Multiple Sclerosis, menopause and hormone replacement therapy	Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis	Multiple sclerosis MedDRA version: 17.1;Level: LLT;Classification code 10064137;Term: Progression of multiple sclerosis;System Organ Class: 100000004852 MedDRA version: 17.1;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Femoston 2/10 Product Name: Femoston 2/10 INN or Proposed INN: ESTRADIOL HEMIHYDRATE INN or Proposed INN: DYDROGESTERONE Trade Name: Femoston 1/10 Product Name: Femoston 1/10 INN or Proposed INN: ESTRADIOL HEMIHYDRATE INN or Proposed INN: DYDROGESTERONE	Irina Elovaara	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no			Finland
4	EUCTR2006-005460-30-IT (EUCTR)	22/05/2007	27/10/2008	POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUS	POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUS	Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: DEMESTRIL SEPTEM INN or Proposed INN: Estradiol Trade Name: LUTENYL INN or Proposed INN: Nomegestrol	OSPEDALI CIVILI DI LIONE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	300		Italy
5	NCT00127075 (ClinicalTrials.gov)	June 2005	4/8/2005	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	Multiple Sclerosis	Drug: nomegestrol acetate;Drug: estradiol;Drug: placebo	Hospices Civils de Lyon	NULL	Active, not recruiting	18 Years	50 Years	Female	300	Phase 3	France

先頭へ